‘Painless’ eye drops tested to halt vision loss in childhood brain tumor

This study is testing a new type of eye drop called CHF6467, a 'painless' nerve growth factor, to see if it can protect and improve vision in children and young adults (ages 3-40) with optic pathway glioma. The goal is to prevent the vision loss that often occurs with this type of brain tumor by using drops that may help protect the nerves in the eye, rather than shrinking the tumor itself. Participants are randomly assigned to receive either the active eye drops or a placebo (inactive salt solution) for 10 days, and their vision is carefully monitored for 12 weeks.